Parexel’s Post

𝐃𝐢𝐯𝐢𝐧𝐠 𝐢𝐧𝐭𝐨 Personalis, Inc.: 𝐘𝐨𝐮𝐫 𝐏𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐬𝐞𝐝 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞 𝐏𝐨𝐰𝐞𝐫𝐡𝐨𝐮𝐬𝐞🧬 As we continue our exploration of the top 5 molecular diagnostics companies to watch in 2024, today we turn our spotlight to Personalis, Inc. (PSNL). This company isn't just riding the personalised medicine wave – they're building the surfboard! 🏄 𝐖𝐡𝐚𝐭 𝐦𝐚𝐤𝐞𝐬 Personalis, Inc. 𝐭𝐢𝐜𝐤? ⏰ Their claim to fame is the Personalis NeXT Platform, a comprehensive tool that analyses a patient's DNA, RNA, and protein data to provide tailored insights for treatment decisions. Think of it as a high-tech crystal ball for doctors, offering a glimpse into the most effective therapies for each individual patient. 𝐏𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐬 𝐢𝐧 𝐀𝐜𝐭𝐢𝐨𝐧 💊 𝑷𝒓𝒆𝒄𝒊𝒔𝒊𝒐𝒏 𝑶𝒏𝒄𝒐𝒍𝒐𝒈𝒚:  Personalis helps oncologists navigate the complex world of cancer treatment by identifying targeted therapies, predicting response to drugs, and monitoring tumor evolution. 𝑰𝒎𝒎𝒖𝒏𝒐-𝑶𝒏𝒄𝒐𝒍𝒐𝒈𝒚: ️They're also at the forefront of immuno-oncology, analysing a patient's immune profile to predict who might benefit from immunotherapy and how to optimise these treatments. 𝑪𝒍𝒊𝒏𝒊𝒄𝒂𝒍 𝑻𝒓𝒊𝒂𝒍𝒔: Personalis partners with biopharma companies to design and accelerate clinical trials by identifying the right patients for these studies based on their unique genomic profiles. 𝐖𝐡𝐚𝐭'𝐬 𝐃𝐫𝐢𝐯𝐢𝐧𝐠 𝐏𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐬' 𝐆𝐫𝐨𝐰𝐭𝐡? 🌱 𝑷𝒂𝒓𝒕𝒏𝒆𝒓𝒔𝒉𝒊𝒑𝒔 𝒈𝒂𝒍𝒐𝒓𝒆: Think major collaborations with pharma giants like Roche and AstraZeneca, solidifying their position in the industry. 𝑫𝒂𝒕𝒂 𝒂𝒅𝒗𝒂𝒏𝒕𝒂𝒈𝒆: They've amassed a massive trove of genomic and clinical data, which they leverage to develop powerful algorithms and insights. 𝑭𝒐𝒄𝒖𝒔 𝒐𝒏 𝒖𝒏𝒎𝒆𝒕 𝒏𝒆𝒆𝒅𝒔: Personalis tackles challenges like late-stage cancer and resistance to therapy, where traditional approaches often fall short. 𝐏𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐬 𝐛𝐲 𝐭𝐡𝐞 𝐍𝐮𝐦𝐛𝐞𝐫𝐬 (2023) 🚀 -  5̳4̳%̳ ̳r̳e̳v̳e̳n̳u̳e̳ ̳g̳r̳o̳w̳t̳h̳ – impressive even in this booming market! -  O̳v̳e̳r̳ ̳1̳0̳0̳ ̳p̳a̳r̳t̳n̳e̳r̳s̳h̳i̳p̳s̳with leading cancer centers and pharma companies. -  5̳x̳ ̳i̳n̳c̳r̳e̳a̳s̳e̳ ̳i̳n̳ ̳c̳l̳i̳n̳i̳c̳a̳l̳ ̳t̳r̳i̳a̳l̳ ̳p̳a̳r̳t̳i̳c̳i̳p̳a̳t̳i̳o̳n̳ for patients using the Personalis NeXT Platform. 𝐅𝐮𝐭𝐮𝐫𝐞 𝐎𝐮𝐭𝐥𝐨𝐨𝐤 🚀 𝑪𝒐𝒏𝒕𝒊𝒏𝒖𝒆𝒅 𝒎𝒂𝒓𝒌𝒆𝒕 𝒆𝒙𝒑𝒂𝒏𝒔𝒊𝒐𝒏: Personalis is eyeing both geographical and clinical space growth, targeting new cancer types and applications. 𝑨𝑰-𝒑𝒐𝒘𝒆𝒓𝒆𝒅 𝒂𝒅𝒗𝒂𝒏𝒄𝒆𝒎𝒆𝒏𝒕𝒔: Expect even more sophisticated algorithms and insights as they harness the power of artificial intelligence. 𝑷𝒆𝒓𝒔𝒐𝒏𝒂𝒍𝒊𝒔𝒆𝒅 𝒎𝒆𝒅𝒊𝒄𝒊𝒏𝒆 𝒎𝒂𝒊𝒏𝒔𝒕𝒓𝒆𝒂𝒎𝒊𝒏𝒈: With Personalis leading the charge, personalised medicine is poised to become the standard of care, not just a dream. 💼 𝐂𝐄𝐎: Christopher Hall https://lnkd.in/e_XknAmn #moleculardiagnostics #personalisedmedicine #precisiononcology #cancercare

CEO Spotlight on clinical development milestones in 2024: “Genprex continues to make progress across a number of areas critical to advancing our novel #genetherapies in #oncology and #diabetes. So far this year, we have opened enrollment and have begun treating patients in two new lung cancer clinical trials, while we continued to treat patients in a third lung cancer clinical trial. We have partnered with a large network of community-based oncology practices to broaden our clinical study reach. We have also expanded our preclinical programs into new therapeutic indications, presenting positive preclinical data supporting our technologies used in these programs at one of the largest and most attended cancer research conferences. In addition, we’ve strengthened our global intellectual property estate, which builds protection for our lead drug candidate. We look forward to achieving a number of important catalysts in the coming months that will further position Genprex as a leader in gene therapy,” said Ryan Confer, President and Chief Executive Officer at Genprex. Read more in the press release here: https://ow.ly/irYu50SrPr0 #ClinicalResearch

In a chat with STAT's Adam Feuerstein, Dr. Peter Marks Senior FDA Official discusses Gene Therapy's explosive growth, and the number of approvals on the horizon to treat a multitude of diseases. It was inspiring to see the regulatory landscape evolving to support this new frontier. Dr.Peter Marks indicated that even if the data aren't "perfect" the agency is ready to approve the therapies if the preponderance of evidence supports approval, especially Sarepta Therapeutics Gene Therapy. DMD is a horrible disease and Sarepta's drug will give hope to parents of children stricken with this genetic condition. I 100% agree with Dr. Marks - this deserves to be commercialized. Furthermore, Dr, Marks addressed the benefits of CAR-T therapies for blood cancers and autoimmune diseases still believed to OUTWEIGH the risks. The FDA is investigating 22 cases of blood cancer post-CAR-T therapy, with indications of a casual relationship in some cases. Warning labels for secondary cancers added to CAR-T therapies; increased safety monitoring may be required. 2023 was a breakthrough year for Cell & Gene Therapies with seven FDA approvals in the US and one in the EU. In 2024, the sector could see up to 17 approvals including the first-ever approval of adoptive cell therapy for solid tumors and the first US approval of an allogeneic T-cell therapy. #FDA #CellandGeneTherapies #CellTherapy #GeneTherapy #Immunology #SolidTumors #ClinicalResearch #TCells #Cart

This is a very nice interview article that is about how metabolomics screening can benefit cancer therapy. #cancer #health #metabolome

We developed (no of samples = 91) and validated (no of samples = 761) a novel machine-learning 15-Gene signature in clear cell renal cell carcinoma (ccRCC), which is independently associated with worse disease-free and disease-specific survival in ccRCC patients.

🌻 🌻 🌻 New opportunity for advancing precision medicine targeted therapy and immunotherapy. Integration of ctDNA tracking helps clinicians to further monitor treatment response and ultimately provide well-rounded care to cancer patients. https://lnkd.in/gMHJgemV #comprehensive #genomic #profiling, #tumor #mutationalburden, #microsatellite #instability, #minimal #residualdisease, #ctdna (circulating tumor DNA), #targetedtherapy # immunotherapy, # immune checkpoint inhibitor (ICI)

We posted our pre-print on identifying responders in clinical trials using geometrical learning. Our methods detect response in a Pfizer clinical trial extremely well: https://lnkd.in/e-4cQdUs The goal of our technology is to get cancer patients the best treatment based on their individual tumor responses. This can potentially get more cancer drugs approved by identifying the patient responders to each compound, thereby improving efficacy. We work with pharma companies on clinical trials to identify subgroups of responders in Phase II/III trials, and also to review failed trials that might be revived in a subgroup of ~20-50% of patients who had notable response - characterizing these patients by their tumor signatures. Thanks to Wojciech Chacholski, my co-founder at DatAnon and co-author of the paper, for all the hard work! #cancer #oncology #clinicaltrials #precisionmedicine #pharma #dataanalytics #clinicalresearch #drugdiscovery #patientresponder

“Smaller, safer plasmid DNA backbones are expanding the toolkit for CAR-T developers, helping them reach their goal of bringing life-saving cell therapies to a broader population of cancer patients.” CAR-T therapy holds tremendous promise, but its development also involves many complexities. As we strive to usher in more CAR-T innovations that will bring new cures and treatment for patients, plasmid DNA will play a critical role. Venkata Shravan K Indurthi, Chief Scientific Officer here at Aldevron, recently wrote about the importance of #plasmidDNA in CAR-T therapy development in @BioCompare here: https://lnkd.in/gKVMPCTm #CART #plasmid

𝐈𝐧𝐭𝐫𝐨𝐝𝐮𝐜𝐢𝐧𝐠 𝐊𝐀𝐑𝐊 𝐃𝐱-𝐂𝐆𝐏: 𝐑𝐞𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐢𝐳𝐢𝐧𝐠 𝐂𝐚𝐧𝐜𝐞𝐫 𝐁𝐢𝐨𝐦𝐚𝐫𝐤𝐞𝐫 𝐓𝐞𝐬𝐭𝐢𝐧𝐠 𝐰𝐢𝐭𝐡 #𝐍𝐆𝐒 𝐔𝐧𝐥𝐨𝐜𝐤𝐢𝐧𝐠 𝐏𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐳𝐞𝐝 𝐂𝐚𝐧𝐜𝐞𝐫 𝐂𝐚𝐫𝐞 𝐰𝐢𝐭𝐡 𝐊𝐀𝐑𝐊 𝐃𝐱-𝐂𝐆𝐏 We're thrilled to introduce KARK Dx-CGP, a groundbreaking test that empowers clinicians with a comprehensive approach to cancer biomarker testing. This cost-effective solution integrates Next-Generation Sequencing (NGS) technology to analyze a meticulously curated pan-cancer gene panel exceeding 200+ key genes. 𝐊𝐞𝐲 𝐛𝐞𝐧𝐞𝐟𝐢𝐭𝐬 𝐨𝐟 𝐊𝐀𝐑𝐊 𝐃𝐱-𝐂𝐆𝐏: 𝐃𝐞𝐦𝐨𝐜𝐫𝐚𝐭𝐢𝐳𝐞𝐬 𝐜𝐚𝐧𝐜𝐞𝐫 𝐛𝐢𝐨𝐦𝐚𝐫𝐤𝐞𝐫 𝐭𝐞𝐬𝐭𝐢𝐧𝐠: Makes advanced NGS technology accessible for a wider range of patients. 𝐒𝐨𝐥𝐢𝐝 & 𝐁𝐥𝐨𝐨𝐝-𝐁𝐚𝐬𝐞𝐝 𝐂𝐚𝐧𝐜𝐞𝐫 𝐃𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧: Analyzes both solid tumor and blood samples, offering flexibility in testing options. 𝐏𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐳𝐞𝐝 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐏𝐥𝐚𝐧𝐧𝐢𝐧𝐠: Identifies mutations in DNA samples with exceptional sensitivity (as low as 5%), enabling tailored treatment strategies. 𝐅𝐃𝐀 & 𝐍𝐂𝐂𝐍-𝐀𝐩𝐩𝐫𝐨𝐯𝐞𝐝 𝐓𝐚𝐫𝐠𝐞𝐭𝐬: Focuses on a panel aligned with leading regulatory and oncology guidelines. 𝐊𝐀𝐑𝐊 𝐃𝐱-𝐂𝐆𝐏 𝐞𝐦𝐩𝐨𝐰𝐞𝐫𝐬 𝐚 𝐧𝐞𝐰 𝐞𝐫𝐚 𝐨𝐟 𝐩𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐨𝐧𝐜𝐨𝐥𝐨𝐠𝐲, 𝐩𝐚𝐯𝐢𝐧𝐠 𝐭𝐡𝐞 𝐰𝐚𝐲 𝐟𝐨𝐫: 🔬𝐄𝐚𝐫𝐥𝐲 𝐜𝐚𝐧𝐜𝐞𝐫 𝐝𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧 🔬𝐈𝐦𝐩𝐫𝐨𝐯𝐞𝐝 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐨𝐮𝐭𝐜𝐨𝐦𝐞𝐬 🔬𝐄𝐧𝐡𝐚𝐧𝐜𝐞𝐝 𝐩𝐚𝐭𝐢𝐞𝐧𝐭 𝐜𝐚𝐫𝐞 𝐑𝐞𝐚𝐝𝐲 𝐭𝐨 𝐥𝐞𝐚𝐫𝐧 𝐦𝐨𝐫𝐞? Contact us today to discuss how KARK Dx-CGP can benefit your practice and patients. 𝐏𝐡𝐨𝐧𝐞: 9830837774 𝐄𝐦𝐚𝐢𝐥 : info@diversegenomics.in #CancerScreening #CancerBiomarkers #PrecisionOncology #PersonalizedMedicine #KARKDx #CGP #NextGenDiagnostics #earlydetection